A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Conditions

Moderate-to-Severe Atopic Dermatitis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nektar Investigative Site, The Bronx, New York, United States

Study leads

Study Director
Nektar Therapeutics

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

St. Petersburg, United States

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · North Little Rock, United States

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Adolescents With Moderate-to-severe Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE3

Shenyang, China · Shanghai, China

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Abroad (travel likely)RecruitingPHASE2

Fountain Valley, United States · Fremont, United States